Stock Financial Ratios, Dividends, Split History

DSPG / DSP Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)268.16
Enterprise Value ($M)246.83
Book Value ($M)146.25
Book Value / Share6.45
Price / Book1.82
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 22,432,660
Weighted Average Number Of Diluted Shares Outstanding 22,229,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 22,725,242
Weighted Average Number Of Shares Outstanding Basic 22,229,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.02
Balance Sheet (mrq) ($M)
Quick Ratio3.75
Current Ratio4.23
Income Statement (mra) ($M)
Operating Income-4.76
Net Income-3.00
Earnings Per Share Diluted-0.14
Earnings Per Share Basic-0.14
Cash Flow Statement (mra) ($M)
Cash From Operations8.50
Cash from Investing-2.06
Cash from Financing-2.06
Identifiers and Descriptors
Central Index Key (CIK)915778

Split History

Stock splits are used by DSP Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Logistics start-up Locus raises $4 million from and others

2018-06-04 livemint
Bengaluru: Logistics platform Locus has raised $4 million in a fresh round of funding from US-based early stage investor, Recruit Strategic Partners, pi Ventures and Hemendra Kothari of DSP Group. (1-0)

This week in MFs: Sector buzzing with news on stake buy to stake sale

2018-05-12 moneycontrol
In the week gone by, the mutual fund sector was gung-ho with news on stake buy to stake sale to resignations to appointments. (35-0)

BlackRock leads race to acquire IDFC AMC; Reliance MF out of fray

2018-05-10 moneycontrol
Global asset manager BlackRock Inc has emerged as a front runner to acquire IDFC Asset Management Company, sources told Moneycontrol. (35-0)

BlackRock to Sell 40% Stake in Joint Venture With DSP Group

2018-05-08 zacks
BlackRock, Inc. (BLK - Free Report) recently agreed to sell its 40% stake in DSP BlackRock Investment Managers to the DSP Group, headed by Hemendra Kothari, thereby exiting the Indian mutual fund business. DSP BlackRock is a joint venture between BlackRock and the DSP Group, with total assets of nearly Rs. 1.1 trillion, including mutual funds, alternative investment funds (AIFs), and assets under advisory services. (92-0)

Deals buzz: Carlyle may close new Asia fund at $6.5 billion

2018-05-08 livemint
Mint brings to you your daily dose of top deals reported by newsrooms across the country. (123-0)

CUSIP: 23332B106